Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's antibody-drug conjugate, Adcetrix, in combination with a chemotherapy regimen in ...

While Takeda is not “laser focused” on one mechanism, Warren said the company is “very interested” in checkpoint inhibitors and CAR-T therapies.

Appellate Court upholds decision in first-ever non-settlement national RICO class action lawsuit certified against a major ...

The global Alagille syndrome market is experiencing significant growth driven by rising awareness, advancements in diagnostic tools, and increased adoption of genetic testing. The market's expansion ...

With the FDA's approval of hereditary angioedema preventative treatment Andembry, CSL is ready to take on Takeda’s ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse generics. Learn why TAK stock is a buy.

TOKYO -- Takeda Pharmaceutical last week set the terms for the issuance of three tranches of straight bonds totaling 184 billion yen ($1.27 billion). But the Japanese drugmaker fell short of its 200 ...

Takeda chief financial officer, Milano Furuta, commented: “Takeda's success in delivering revenue and Core Operating Profit growth in FY2024 and our outlook for broadly flat revenue and profit ...

A third-party health insurance payer can proceed as a class in a racketeering lawsuit against Takeda Pharmaceuticals Co. and Eli Lilly & Co., a federal appeals panel ruled Monday.